Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: Potential for savings

This publication has 28 references indexed in Scilit:

• Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants
  Pediatrics, 1998
• Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis
  Pediatrics, 1997
• Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection
  The Journal of Pediatrics, 1996
• Association of Invasive Pneumococcal Disease with Season, Atmospheric Conditions, Air Pollution, and the Isolation of Respiratory Viruses
  Clinical Infectious Diseases, 1996
• Viral etiology and epidemiology of acute lower respiratory tract infections in Korean children
  The Pediatric Infectious Disease Journal, 1995
• The morality of efficiency in health care—some uncomfortable implications
  Health Economics, 1992
• Variation in severity of respiratory syncytial virus infections with subtype
  The Journal of Pediatrics, 1990
• Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis
  The Journal of Pediatrics, 1988
• Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy.
  BMJ, 1982
• Increased incidence of bronchial reactivity in children with a history of bronchiolitis
  The Journal of Pediatrics, 1981